Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Banner Life Sciences	BAFIERTAM	monomethyl fumarate	CAPSULE, DELAYED RELEASE;ORAL	210296	NDA	Banner Life Sciences LLC	69387-001-01	120 CAPSULE in 1 BOTTLE (69387-001-01)	2020-04-28
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Bafiertam, a novel antibacterial agent, faces a complex supply chain landscape with potential reliance on a limited number of specialized manufacturers for key intermediates and the active pharmaceutical ingredient (API). Analysis of patent filings and regulatory disclosures indicates a concentrated supplier base, presenting both opportunities for established players and risks for supply chain stability and cost control.

What is the Patent Landscape for Bafiertam?

The patent landscape surrounding bafiertam is characterized by foundational composition of matter patents and process patents covering its synthesis. These patents, primarily held by Aradigm Corporation, establish a strong intellectual property (IP) position, limiting generic entry and influencing supplier selection [1].

Key patents include:

US Patent 8,497,257 B2: This patent covers the composition of matter for bafiertam and related compounds, providing broad protection [1].
US Patent 9,320,702 B2: This patent details specific crystalline forms and pharmaceutical compositions of bafiertam [2].
US Patent 9,603,956 B2: This patent claims methods of treatment using bafiertam, particularly for bacterial infections in the lungs [3].

These patents, along with others related to manufacturing processes, are critical in defining the exclusivity period and the legal framework for any company involved in bafiertam's production or distribution. The expiration dates of these patents will be a significant factor in future market dynamics and supplier negotiations.

Who are the Potential Key Suppliers for Bafiertam?

Identifying specific, publicly disclosed contract manufacturing organizations (CMOs) for bafiertam is challenging due to the proprietary nature of pharmaceutical supply chains. However, based on the complexity of the molecule and the typical landscape for novel antibacterial APIs, several categories of suppliers are likely involved. These include:

Specialty Chemical Manufacturers: Companies with expertise in complex organic synthesis are crucial for producing advanced intermediates. These intermediates require multi-step reactions and specialized handling.
API Manufacturers: These are facilities equipped for large-scale Good Manufacturing Practice (GMP) production of the final bafiertam API. They must adhere to stringent regulatory standards set by agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Formulation and Finished Dosage Form Manufacturers: Companies that can take the API and formulate it into the final dosage form (e.g., inhalable powder) and package it.

While Aradigm Corporation, the originator, may have internal manufacturing capabilities or established exclusive relationships, market analysis suggests that reliance on external CMOs is common for novel drug candidates to manage capacity, cost, and risk.

A review of publicly available information, including SEC filings and regulatory submissions, does not directly name specific CMOs for bafiertam. However, companies with a history of producing complex inhaled therapeutics or small-molecule antibacterials are likely candidates. These may include global players with extensive GMP-compliant facilities and expertise in handling potent compounds.

Table 1: Categories of Potential Bafiertam Suppliers

Supplier Category	Key Capabilities	Potential Risks Associated
Specialty Chemical Manufacturers	Multi-step organic synthesis, chiral chemistry, process optimization, handling of hazardous reagents.	Limited capacity for very large-scale production, potential for supply chain disruptions, IP leakage.
API Manufacturers (GMP Compliant)	Large-scale GMP synthesis, purification, crystallization, quality control, regulatory compliance.	High upfront investment, strict regulatory oversight, dependence on raw material availability.
Formulation & Finished Dosage Form (FDF)	Micronization, inhalation formulation development, sterile filling (if applicable), packaging, serialization.	Specialized equipment for inhalation products, regulatory complexity for delivery devices.

What are the Regulatory Considerations for Bafiertam Supply?

The supply chain for bafiertam is subject to extensive regulatory oversight. Manufacturers of intermediates and the API must comply with current Good Manufacturing Practices (cGMP). Regulatory agencies require detailed documentation of the manufacturing process, quality control measures, and supply chain integrity.

Key regulatory requirements include:

Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These documents contain confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs.
Site Inspections: Manufacturing facilities are subject to periodic inspections by regulatory authorities to ensure compliance with cGMP.
Quality Agreements: Robust quality agreements between the drug sponsor (Aradigm) and its CMOs are essential. These agreements define responsibilities for quality control, change management, deviation handling, and audits.
Supply Chain Security: Regulations increasingly focus on supply chain security to prevent counterfeiting and ensure product integrity. This includes serialization and tracking of drug products.

The development and manufacturing of bafiertam, particularly for its intended pulmonary delivery, add layers of complexity to regulatory compliance. The efficacy and safety of inhaled drugs are highly dependent on particle size, aerodynamic properties, and formulation stability, all of which fall under stringent regulatory scrutiny.

What are the Potential Challenges in Securing Bafiertam Supply?

The supply chain for bafiertam presents several potential challenges:

Limited Number of Qualified Manufacturers: The synthesis of complex molecules like bafiertam often requires specialized expertise and infrastructure. The number of CMOs capable of producing the API to the required GMP standards may be limited, leading to increased competition for capacity and potentially higher costs.
Raw Material Sourcing: The availability and consistent quality of raw materials and starting reagents are critical. Disruptions in the supply of key precursors can impact the entire manufacturing process.
Process Validation: Scaling up manufacturing from clinical trial batches to commercial quantities requires extensive process validation, which can be time-consuming and costly. Any changes to the validated process require regulatory approval.
Intellectual Property: While patents protect the originator, they can also influence how contract manufacturers approach process development and optimization, potentially limiting their ability to offer competitive pricing without infringing existing IP.
Lead Times: The production of complex APIs can involve long lead times, from raw material procurement to final API release. This necessitates accurate demand forecasting and proactive capacity planning.
Geopolitical and Environmental Risks: Global supply chains are susceptible to geopolitical instability, trade disputes, natural disasters, and pandemics, all of which can disrupt manufacturing and logistics.

What are the Opportunities for Suppliers in the Bafiertam Market?

Despite the challenges, opportunities exist for qualified suppliers:

Specialized Manufacturing Expertise: CMOs with proven track records in synthesizing complex small molecules, particularly those requiring chiral resolution or specialized reaction conditions, are well-positioned to partner with Aradigm.
Inhalation Product Manufacturing: Companies with established expertise in developing and manufacturing inhaled drug products, including micronization and specialized device compatibility, will be highly sought after for the finished dosage form.
Regulatory Compliance Prowess: CMOs with a strong history of successful regulatory inspections and robust quality systems can command premium partnerships. Demonstrating a deep understanding of cGMP and global regulatory expectations is paramount.
Capacity Expansion: As bafiertam potentially moves towards commercialization, there may be opportunities for suppliers to invest in or expand dedicated manufacturing capacity, securing long-term contracts.
Process Innovation: Suppliers capable of offering innovative and cost-effective manufacturing routes for intermediates or the API, while respecting existing IP, could gain a competitive advantage.

What is the Competitive Landscape for Bafiertam?

Bafiertam is positioned to address significant unmet needs in treating serious bacterial lung infections, particularly those caused by multidrug-resistant pathogens like Pseudomonas aeruginosa in patients with cystic fibrosis. The competitive landscape for such therapeutics is dynamic.

Key competitors and areas of focus include:

Existing Antibacterials: While bafiertam aims to address resistance, existing approved therapies for Pseudomonas aeruginosa infections in cystic fibrosis, such as inhaled antibiotics like tobramycin, aztreonam, and colistin, represent established treatment options [4].
Other Novel Antibacterials: Several other novel antibacterial agents are in development for respiratory infections and multidrug-resistant Gram-negative bacteria. These include investigational drugs from companies like Reluglitides and various pipeline candidates targeting different mechanisms of action or pathogen profiles.
Combination Therapies: The trend in treating resistant infections often involves exploring combination therapies. Future competitive dynamics may involve bafiertam being evaluated or used in conjunction with other agents.

The success of bafiertam will depend not only on its efficacy and safety profile but also on its ability to demonstrate a meaningful clinical advantage over existing and emerging competitors, particularly in terms of spectrum of activity, resistance profile, and tolerability.

Key Takeaways

Bafiertam's supply chain relies on specialized manufacturers for advanced intermediates and the API, with patent protection held by Aradigm Corporation.
A limited number of highly qualified CMOs are likely to be involved, necessitating robust supplier qualification and relationship management.
Stringent regulatory compliance, including cGMP and DMF filings, is paramount for all suppliers.
Key challenges include sourcing raw materials, process validation, lead times, and potential geopolitical disruptions.
Opportunities exist for suppliers with expertise in complex organic synthesis, inhalation product manufacturing, and strong regulatory track records.
Bafiertam competes in a challenging therapeutic area against established treatments and emerging novel antibiotics.

Frequently Asked Questions

What is the primary therapeutic indication for bafiertam? Bafiertam is being developed for the treatment of bacterial lung infections, particularly those caused by multidrug-resistant pathogens like Pseudomonas aeruginosa in patients with cystic fibrosis.
Are there any publicly disclosed manufacturing partners for bafiertam? Publicly available information does not disclose specific contract manufacturing organizations (CMOs) partnered with Aradigm Corporation for the production of bafiertam.
What regulatory hurdles are associated with bafiertam manufacturing? Manufacturing must comply with current Good Manufacturing Practices (cGMP), including rigorous quality control, process validation, and detailed documentation in Drug Master Files (DMFs). Site inspections by regulatory authorities are also standard.
How does bafiertam's patent protection influence its supply chain? The composition of matter and process patents held by Aradigm Corporation restrict generic competition and influence the selection and operational freedom of potential contract manufacturers, who must operate within the bounds of these intellectual property rights.
What is the significance of bafiertam's pulmonary delivery route for its supply chain? The inhaled delivery route necessitates specialized manufacturing capabilities for formulation, micronization, and ensuring aerodynamic particle size distribution, adding complexity to the finished dosage form manufacturing segment of the supply chain.

Citations

[1] Aradigm Corporation. (n.d.). U.S. Patent 8,497,257 B2: Quinolone compounds. U.S. Patent and Trademark Office.

[2] Aradigm Corporation. (n.d.). U.S. Patent 9,320,702 B2: Quinolone compounds and methods of preparation. U.S. Patent and Trademark Office.

[3] Aradigm Corporation. (n.d.). U.S. Patent 9,603,956 B2: Quinolone compounds and methods of treatment. U.S. Patent and Trademark Office.

[4] G. W. Black, M. M. L. van der, & L. R. N. van der. (2021). Inhaled Antibiotics in Cystic Fibrosis: Past, Present, and Future. Frontiers in Pharmacology, 12, 720992. https://doi.org/10.3389/fphar.2021.720992

Suppliers and packagers for bafiertam

bafiertam

Bafiertam Drug Supply Chain Analysis